Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
131.20    -0.40 (-0.30%)
Bid:
130.80
Ask:
131.20
Spread: 0.40 (0.306%)
Market Cap: £319.36m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Holding(s) in Company

8 May 2026 07:00

RNS Number : 5074D
PureTech Health PLC
08 May 2026
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BY2Z0H74

Issuer Name

PURETECH HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Briarwood Chase Management LLC

City of registered office (if applicable)

New York

Country of registered office (if applicable)

USA

4. Details of the shareholder

Name

City of registered office

Country of registered office

Morgan Stanley & Co., LLC

New York

USA

5. Date on which the threshold was crossed or reached

06-May-2026

6. Date on which Issuer notified

07-May-2026

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

5.093400

0.000000

5.093400

12398267

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BY2Z0H74

12398267

5.093400

Sub Total 8.A

12398267

5.093400%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aalap Mahadevia

5.093400

5.093400%

Briarwood Chase Management LLC

5.093400

5.093400%

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

07-May-2026

13. Place Of Completion

New York, NY USA

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLARMBTMTBMTLF
Date   Source Headline
28th Oct 201912:07 pmRNSSecond Price Monitoring Extn
28th Oct 201912:02 pmRNSPrice Monitoring Extension
24th Oct 20197:00 amRNSSonde Names Healthcare Tech Exec David Liu as CEO
18th Oct 20194:40 pmRNSSecond Price Monitoring Extn
18th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 20194:40 pmRNSSecond Price Monitoring Extn
4th Oct 20194:35 pmRNSPrice Monitoring Extension
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
2nd Oct 20197:00 amRNSMinority Stake Acquisition & PDMR Notification
1st Oct 20194:40 pmRNSSecond Price Monitoring Extn
1st Oct 20194:35 pmRNSPrice Monitoring Extension
1st Oct 20191:15 pmRNSVor Appoints Senior Cell & Gene Therapy Leaders
1st Oct 20197:00 amRNSTotal Voting Rights
23rd Sep 20194:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20194:35 pmRNSPrice Monitoring Extension
23rd Sep 201912:07 pmRNSSecond Price Monitoring Extn
23rd Sep 201912:02 pmRNSPrice Monitoring Extension
23rd Sep 20197:00 amRNSVedanta Expands Series C with $62.1M Total Raised
16th Sep 20194:40 pmRNSSecond Price Monitoring Extn
16th Sep 20194:35 pmRNSPrice Monitoring Extension
9th Sep 201912:07 pmRNSSecond Price Monitoring Extn
9th Sep 201912:02 pmRNSPrice Monitoring Extension
9th Sep 20197:00 amRNSPureTech Announces Board Change
6th Sep 20194:41 pmRNSSecond Price Monitoring Extn
6th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 201912:07 pmRNSSecond Price Monitoring Extn
4th Sep 201912:02 pmRNSPrice Monitoring Extension
27th Aug 20197:00 amRNSPureTech Health plc Half-Year Report
20th Aug 20197:00 amRNSNotice of Results
19th Aug 201912:02 pmRNSPrice Monitoring Extension
14th Aug 20195:30 pmRNSBTG
7th Aug 20191:40 pmRNSVor Names Biotech Vet Robert Ang President & CEO
1st Aug 20197:00 amRNSTotal Voting Rights
31st Jul 20191:40 pmRNSVor Biopharma Adds R&D Leader Bill Lundberg to BOD
17th Jul 20197:00 amRNSPRTC Acquires Clinical Stage Asset for Lymphedema
11th Jul 20197:00 amRNSPotential US Listing of PureTech Health on Nasdaq
9th Jul 20197:00 amRNSPRTC Immuno-Oncology Programme Granted US Patent
3rd Jul 20197:00 amRNSPRTC's Karuna closes IPO, gross proceeds $102.6M
1st Jul 20197:00 amRNSFirst Patient in Vedanta Food Allergy Study
28th Jun 20197:00 amRNSPureTech's Karuna successfully lists on NASDAQ
20th Jun 20197:00 amRNSPureTech Announces New Corporate HQ/Internal Labs
13th Jun 20197:00 amRNSFollica Positive Interim Data & Plans for Pivotal
3rd Jun 20197:00 amRNSPRTC's Karuna Files Public S1 for NASDAQ IPO
30th May 20197:05 amRNSPRTC to Present at Jefferies US Conference
30th May 20197:00 amRNSResult of AGM
29th May 20197:00 amRNSVor Publishes POC Study in Scientific Journal
21st May 20197:00 amRNSVedanta Presents Expanded Data from Successful Ph1
20th May 20197:00 amRNSPromising Gelesis Data in Chronic Constipation
14th May 20197:00 amRNSGelesis & Vedanta Data at Digestive Disease Week

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.